QQ2 2024 key metrics and qualitative takeaways:
- Revenue: not reported (null). No top-line figure for the quarter, complicating YoY/QoQ revenue analysis.
- Net income: -$0.9079 million for QQ2 2024; QoQ and YoY metrics in the data show a deterioration path (Net income QoQ: -241.86%, YoY: -524.65%).
- Earnings per share (EPS): -$0.0454 basic and diluted; YoY change -521.92%, QoQ change -241.35%.
- Operating income: -$0.5593 million; QoQ change -7.55% (YoY not available).
- EBITDA: -$0.4267 million.
- Gross profit / gross margin: not disclosed (grossProfit = null; grossProfitMargin = 0 in ratio table).
- R&D spend: $243,381; G&A spend: $155,205; total operating expenses: $525,729; total cost and expenses: $559,283.
- Depreciation & amortization: $99,071.
- Cash flow: net cash provided by operating activities $34,284; capex $-47,553; net cash from investing activities $-47,553; net cash provided by financing activities $667,879; effect of foreign exchange on cash around -$465,206; net change in cash $189,404; cash at end of period $2,776,622; free cash flow negative at -$13,269.
- Balance sheet: total assets $4,778,658; total liabilities $4,581,817; total stockholders’ equity $196,841; cash and equivalents $2,776,622; cash and short-term investments $2,776,622; total debt $130,101; net debt negative $2,646,521; retained earnings negative $14,108,458; intangible assets $188,373; accumulated other comprehensive income $611,934; current liabilities $4,581,817; current ratio 0.82; quick ratio 0.82; debt-to-equity 3.09; price-to-book 117.93; enterprise value multiple -169.35; earnings yield implied negative value; shares outstanding 20,000,000.
- Leverage and profitability indicators are highly negative due to the lack of revenue and ongoing R&D investment, with limited visibility on near-term monetization.